Archives
Bradykinin B2 Receptors Modulate Peristalsis in Guinea Pig I
2026-04-28
Bradykinin B2 Receptor-Mediated Modulation of Peristaltic Reflex in the Guinea Pig Ileum
Study Background and Research Question
The peristaltic reflex, a coordinated contraction of longitudinal and circular smooth muscle, is essential for gastrointestinal (GI) motility and transit. While the role of mediators such as acetylcholine and serotonin (5-HT) has been well-characterized, the specific contribution of bradykinin—a nonapeptide involved in inflammation and vascular regulation—remained unclear with respect to peristalsis. Previous research established that bradykinin can contract or relax GI smooth muscle and modulate motility via distinct receptor subtypes (B1 and B2), but whether it directly influences the peristaltic reflex had not been systematically addressed (paper). The central research question of Chan & Rudd (2006) was: Does bradykinin, acting through B1 or B2 receptors, modulate the pressure threshold and execution of the peristaltic reflex in the guinea pig ileum, and how do selective agonists and antagonists affect this process?Key Innovation from the Reference Study
The study is the first to comprehensively dissect the receptor-dependent effects of bradykinin on the peristaltic reflex using a pharmacological approach in an ex vivo model. By comparing the effects of bradykinin and its analogs, along with highly selective B2 and B1 antagonists (FR173657, icatibant for B2; Lys-[des-Arg9, Leu8]-bradykinin for B1), the authors uniquely demonstrate that B2, but not B1, receptors are responsible for bradykinin-mediated inhibition of peristalsis (paper).Methods and Experimental Design Insights
The investigators used isolated segments of guinea pig ileum mounted in organ baths, allowing precise measurement of peristaltic threshold pressure in response to graded intraluminal distension. Test compounds—including bradykinin, kallidin (B2 agonist), [des-Arg9]-bradykinin (B1 agonist), and well-characterized antagonists—were applied serosally. For comparison, morphine (a known inhibitor of peristalsis) and 5-HT (a facilitator) were also tested. The approach enabled quantitative assessment of changes in pressure threshold required to trigger peristalsis under each pharmacological condition, with statistical analysis confirming the significance of observed effects (paper).Protocol Parameters
- assay | Isolated guinea pig ileum organ bath | tissue-based ex vivo applicability | Enables direct measurement of peristaltic threshold and pharmacological modulation | paper
- bradykinin concentration | 1–1000 nM | B2 receptor activation studies | Dose range covers physiological and supra-physiological effects for robust response characterization | paper
- B2 antagonist (FR173657) | 1 and 100 nM | B2 receptor specificity assessment | Demonstrates selectivity and potency of antagonism | paper
- pressure threshold measurement | ΔPa (change in peristaltic threshold) | Functional output for motility | Quantitative, reproducible endpoint for reflex modulation | paper
Core Findings and Why They Matter
Bradykinin and the B2-selective agonist kallidin both significantly increased the pressure threshold for peristalsis, indicating an inhibitory effect on the reflex. At 1000 nM, the maximal increase in threshold was approximately 60 Pa—substantial, though less than that produced by morphine (~130 Pa). In contrast, the B1 agonist [des-Arg9]-bradykinin was inactive, underscoring the selectivity for B2 receptors. B2 antagonists (FR173657 at 1/100 nM, icatibant at 10 nM) effectively reversed the bradykinin-induced inhibition, while the B1 antagonist had no effect (paper). Interestingly, FR173657 alone (at 100 nM) not only blocked bradykinin's inhibition but also facilitated peristalsis, reducing the threshold by ~15 Pa. This duality suggests a tonic inhibitory role for endogenous bradykinin acting via B2 receptors in gut motility regulation. Conversely, 5-HT enhanced peristalsis (EC50 ~38 nM, max reduction ~76 Pa), consistent with established literature. Taken together, these results provide compelling evidence that bradykinin B2 receptor activation suppresses peristaltic reflexes in the guinea pig ileum, while B1 receptors are not involved in this context. This mechanistic clarity has implications for both basic GI physiology and the pharmacological targeting of bradykinin pathways.Comparison with Existing Internal Articles
Several recent reviews and resource articles have explored bradykinin pathway modulation in the context of ACE inhibition and translational research:- Captopril and Bradykinin Modulation: Advanced Insights for ACE Inhibition provides a broader overview of captopril as a potent ACE inhibitor, highlighting its role in bradykinin pathway modulation and apoptosis induction in cancer cells. While this article emphasizes downstream cellular effects, the present study offers direct evidence of bradykinin’s functional impact on gut motility.
- Captopril in Translational Research: From Mechanistic ACE... integrates bradykinin signaling evidence into a cross-domain perspective (hypertension, oncology, GI), but the core mechanistic insight—B2 receptor-mediated inhibition of peristalsis—is uniquely delineated by the referenced primary study.
Limitations and Transferability
While the study provides robust evidence for B2 receptor-mediated inhibition of peristalsis in guinea pig ileum, several limitations should be noted:- Species specificity: Results are based on guinea pig tissue; extrapolation to human GI physiology requires caution and further validation (paper).
- Ex vivo model: Organ bath studies offer precise control but may not capture the full complexity of in vivo neurohumoral interactions.
- Acute pharmacological manipulations: Chronic or pathophysiological conditions (e.g., inflammation, altered receptor expression) could modify the observed responses.